Safety really comes down to proper dosing and patient selection by a licensed provider. A 2025 review that assessed the safety profiles of both drugs found that the most common adverse effects are the same for both tirzepatide and semaglutide, namely, nausea, vomiting and diarrhea
Tirzepatide therapy may be appropriate for adults who: Have a BMI 30 (obesity) Have a BMI 27 with weight-related health conditions (e.g., high blood pressure, Type 2 diabetes, prediabetes) Struggle with persistent weight despite diet and exercise Are committed to integrating lifestyle changes and clinical follow-upA comprehensive medical assessment is necessary to determine safety, dosing, and suitability for treatment
At 10 mg/mL, drawing 10 units gives you 40% of the standard 2.5 mg starting dose
The trials have shown promising results for weight loss, but, like any medication, it may have side effects and other things to consider
Eddie listens intently, provides thoughtful insight, and is fully committed to help his patients achieve the best outcome. Brandi H